title: The need of a new and more physiological preclinical model for Parkinson's disease.
authors.affiliation: Molecular and Clinical Pharmacology, Faculty of Medicine, University of Chile, Independencia 1027, Casilla 70000, Santiago 7, Chile. jsegura@med.uchile.cl.
authors.forename: Juan
authors.initials: J
authors.lastname: Segura-Aguilar
authors.affiliation: Molecular and Clinical Pharmacology, Faculty of Medicine, University of Chile, Independencia 1027, Casilla 70000, Santiago 7, Chile.|Departamento de Ciencia Básicas, Facultad de Ciencias, Universidad Santo Tomas, Santiago, Chile.
authors.forename: Irmgard
authors.initials: I
authors.lastname: Paris
authors.affiliation: Molecular and Clinical Pharmacology, Faculty of Medicine, University of Chile, Independencia 1027, Casilla 70000, Santiago 7, Chile.
authors.forename: Patricia
authors.initials: P
authors.lastname: Muñoz
mesh_terms: D000818:Animals; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D018696:Neuroprotective Agents
keywords: 6-hydroxydopamine; Alpha synuclein; Aminochrome; Autophagy; Dopamine; Dopaminergic neurons; Dyskinesia; Endoplasmic reticulum stress; L-Dopa; MPTP; Mitochondria; Neurodegeneration; Neuroinflammation; Neuromelanin; Oxidation; Oxidative stress; Proteasome